<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332618</url>
  </required_header>
  <id_info>
    <org_study_id>Laboratoires CARILENE</org_study_id>
    <nct_id>NCT00332618</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia</brief_title>
  <official_title>Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires CARILENE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires CARILENE</source>
  <brief_summary>
    <textblock>
      The objective of the trial was to evaluate the efficacy and clinical safety and acceptability&#xD;
      of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference&#xD;
      comparator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xerostomia is due to inadequate (hyposialia) or inexistent (asialia) saliva secretion.&#xD;
&#xD;
      There are may causes. Transitory xerostomia may occur in the presence of anxiety (stage&#xD;
      fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic&#xD;
      disease, certain medicines or to radiotherapy of the head or neck.&#xD;
&#xD;
      Salivation depends upon the autonomic (sympathetic and parasympathetic) nervous system for&#xD;
      its production and on the central nervous system for stimuli-dependant excretion. Substances&#xD;
      acting on alpha an beta sympathetic receptors, whether agonists or antagonists, may induce&#xD;
      hyposialia. Atropine, the main antagonist of the parasympathetic system, is present in many&#xD;
      medicines used for pulmonary, ophthalmic or neurological purposes, potentially causing&#xD;
      hyposialia. Similarly, imipramine antidepressants, phenothiazine neuroleptics, antihistamines&#xD;
      and disopyramide predispose to the onset of hyposialia.&#xD;
&#xD;
      Xerostomia is often accompanied by buccal signs such as impaired sense of taste, halitosis&#xD;
      and buccal ulcers and interferes with functions such as speech, chewing and swallowing.&#xD;
      Because of reduced salivary secretion , there is a disturbance of the microbial colonization&#xD;
      of the buccal cavity. Xerostomia has significant untoward effects on the buccal cavity and&#xD;
      the quality of life of patients.&#xD;
&#xD;
      The basis of the treatment of xerostomia involves the use of saliva substitutes and/or saliva&#xD;
      stimulants. Oxygenated Glycerol Triesters is neither a replacement for nor stimulant of&#xD;
      saliva. It is a lubricant and protective solution for endobuccal spray.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>April 2004</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>74</enrollment>
  <condition>Xerostomia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OXYGENATED GLYCEROL TRIESTERS</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men or women over 18 years of age&#xD;
&#xD;
          -  with a diagnosis requiring the prescription of psychotropies (antidepressants,&#xD;
             tranquilizers, etc) for more than 6 weeks&#xD;
&#xD;
          -  having received no palliative treatment for xerostomia for a minimum of the past 2&#xD;
             weeks&#xD;
&#xD;
          -  having xerostomia meeting the questionnaire selection criteria and the sialometer&#xD;
             method parameters&#xD;
&#xD;
          -  patients legally competent to give their consent&#xD;
&#xD;
          -  capable of and accepting to participate in the trial and capable of and accepting to&#xD;
             answer trial questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  combined treatments incompatible with the trial, un particular alcoholic solutions&#xD;
&#xD;
          -  diabetes, any buccal condition requiring antimicrobial treatment&#xD;
&#xD;
          -  Sj√∂gren's syndrome or othermedical causes of xerostomia&#xD;
&#xD;
          -  current participation in other clinical trials&#xD;
&#xD;
          -  patient suffering from cancer&#xD;
&#xD;
          -  patients with allergy to or known intolerance of any of the constituents of the&#xD;
             investigational products&#xD;
&#xD;
          -  patients treated with pilocarpine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YVES YT TILLET, Expertpharma</last_name>
    <role>Study Director</role>
    <affiliation>WHITE TILLET Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Baptiste JO Orler, Psychiatrist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU HOPITAL DES BROUSSAILLES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Hopital Des Broussailles</name>
      <address>
        <city>Cannes</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Fox PC. Management of dry mouth. Dent Clin North Am. 1997 Oct;41(4):863-75. Review.</citation>
    <PMID>9344281</PMID>
  </reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>May 31, 2006</study_first_submitted>
  <study_first_submitted_qc>May 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>June 6, 2006</last_update_submitted>
  <last_update_submitted_qc>June 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2006</last_update_posted>
  <keyword>MULTICENTER</keyword>
  <keyword>CONTROLLED</keyword>
  <keyword>PARALLEL GROUPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

